Sargent Bickham Lagudis’s Vertex Pharmaceuticals VRTX Stock Holding History

Sargent Bickham Lagudis’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$58.3K	Hold	202	–	–	﹤0.01%	418
2022 Q3	$58K	Sell	202 -20	-9%	-$5.75K	0.01%	386
2022 Q2	$63K	Buy	222 +83	+60%	+$22.2K	0.01%	379
2022 Q1	$36K	Hold	139	–	–	﹤0.01%	519
2021 Q4	$31K	Hold	139	–	–	﹤0.01%	542
2021 Q3	$25K	Hold	139	–	–	﹤0.01%	571
2021 Q2	$28K	Hold	139	–	–	﹤0.01%	564
2021 Q1	$30K	Hold	139	–	–	﹤0.01%	528
2020 Q4	$33K	Hold	139	–	–	﹤0.01%	485
2020 Q3	$38K	Hold	139	–	–	﹤0.01%	424
2020 Q2	$40K	Hold	139	–	–	﹤0.01%	383
2020 Q1	$33K	Hold	139	–	–	﹤0.01%	392
2019 Q4	$30K	Hold	139	–	–	﹤0.01%	461
2019 Q3	$24K	Hold	139	–	–	﹤0.01%	449
2019 Q2	$25K	Hold	139	–	–	﹤0.01%	456
2019 Q1	$26K	Buy	139 +20	+17%	+$3.69K	﹤0.01%	481
2018 Q4	$20K	Hold	119	–	–	﹤0.01%	490
2018 Q3	$23K	Hold	119	–	–	﹤0.01%	480
2018 Q2	$20K	Hold	119	–	–	﹤0.01%	486
2018 Q1	$19K	Hold	119	–	–	﹤0.01%	486
2017 Q4	$18K	Hold	119	–	–	﹤0.01%	514
2017 Q3	$18K	Hold	119	–	–	﹤0.01%	516
2017 Q2	$15K	Hold	119	–	–	﹤0.01%	525
2017 Q1	$13K	Hold	119	–	–	﹤0.01%	554
2016 Q4	$9K	Hold	119	–	–	﹤0.01%	579
2016 Q3	$10K	Hold	119	–	–	﹤0.01%	585
2016 Q2	$10K	Hold	119	–	–	﹤0.01%	554
2016 Q1	$9K	Buy	+119	New	+$10.8K	﹤0.01%	583

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sargent Bickham Lagudis's VRTX Position: Q4 2022 in Review

Sargent Bickham Lagudis held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2022 at 202 shares worth $58.3K. The position accounts for ﹤0.01% of the portfolio, ranked #418.

Sargent Bickham Lagudis first reported a position in VRTX in Q1 2016 and has held it in 28 quarters since. The position peaked at $63K in Q2 2022. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Sargent Bickham Lagudis held 202 shares of Vertex Pharmaceuticals worth $58.3K as of Q4 2022.
Sargent Bickham Lagudis left its Vertex Pharmaceuticals share count unchanged in Q4 2022.
Vertex Pharmaceuticals made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #418 holding.
Sargent Bickham Lagudis first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 28 quarters since.
Sargent Bickham Lagudis's Vertex Pharmaceuticals position peaked at $63K in Q2 2022.
1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.